Main Page Article Search E-Lerts™ Newsletter: Current E-Lerts™ Newsletter Archives E-Lerts™ Newsletter Recipes Archives Defeat Diabetes® E-Lerts™ Newsletter Subscribe Defeat Diabetes ® News by Daniel H. Rasolt Books You Can Use™ Subscribe to Defeat Diabetes Foundation Mailings
About Diabetes Body Care Children Complications Defeat Diabetes Foundation Drugs    » ACE Inhibitor    » Actos    » Alternative Medicine    » Aspirin    » Avandia    » Byetta    » Drugs    » Exenatide    » Glargine    » Glucophage    » Insulin    » Januvia    » Lantus    » Liraglutide    » Metformin    » Recall    » Research    » Rosiglitazone    » Self-Management    » Statins    » Sulfonylureas    » Victoza Elderly E-Lerts™ Governments & Organizations Health & Fitness Insulin MADDCAP™ Mr. Diabetes® Nutrition Obesity Other Diseases Pregnancy Research Risks Self-Management Supplements Type 1 Warning Signs

 

 

 

     

Drugs » Avandia

Search our News Articles Archives for diabetes and health news. Search by word or phrase.  The latest article will appear first.

Search For:  

Search in all categories / subcategories
Search in current category / subcategory

Combo of Diabetes Drugs Increases Mortality Posted: Thursday, August 21, 2008

Combination treatment for type 2 diabetes using two classes of drugs -- metformin and sulfonylureas -- may increase the risk of hospitalization for cardiovascular disease and mortality, according to a new report.

More Evidence of Increased Fractures With Thiazolidinediones Posted: Wednesday, June 25, 2008

Further evidence that long-term use of the thiazolidinediones rosiglitazone and pioglitazone may increase risk of fractures (particularly of the hip and wrist) has come from a new case-control study.

Glitazones No Better than Older Drugs for Type 2 Diabetes Posted: Friday, April 18, 2008

The class of glitazone diabetes drugs offer no benefits as monotherapy compared with older, less expensive drugs, according to the authors of an analysis of data from recent clinical trials.

Rosiglitazone to Stay on US Market With New Warnings About MI Posted: Friday, November 23, 2007

The FDA has decided to allow the diabetes drug rosiglitazone (Avandia, GlaxoSmithKline) to stay on the market with increased warnings about the risk of cardiovascular events, while further studies are conducted to investigate the issue. A myocardial infarction warning will be added to the black box warning.

Rosiglitazone Seen No Better than Other Drugs in Diabetic Control Posted: Friday, August 03, 2007

The data from 8,432 patients found that glycemic control, as measured by levels of HbA1c, was no better in patients given rosiglitazone than those given other antidiabetic drugs, found Bernd Richter, M.D., of the University of Duesseldorf, and colleagues.

FDA To Ask If Avandia Should Stay In The Market Posted: Friday, August 03, 2007

The FDA will ask outside advisers if GlaxoSmithKline Plc's diabetes drug Avandia should stay on the market or be subject to new warnings or limits.

Avandia Update July 07: New Information - Side Effects Tripled Posted: Thursday, July 19, 2007

In the month after a surprising analysis revealed possible heart risks from the diabetes drug Avandia, reports of side effects to federal regulators tripled.

 

 

 

 

 

 Costa Rica Travel Corp. will donate a portion of the proceeds to and is a sponsor of Defeat Diabetes Foundation.